The bristol-myers squibb (bmy) stock rating reaffirmed by argus – bangaloreweekly data recovery android app

Argus reiterated their buy rating on shares of bristol-myers squibb (NYSE:BMY) in a report published on wednesday morning. They currently have a $66.43 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $75.00.

BMY has been the topic of several other reports. Jefferies group set a $72.00 target price on shares of bristol-myers squibb and gave the stock a hold rating in a research note on monday, february 26th. Bank of america upped their target price on shares of bristol-myers squibb from $64.00 to $68.00 and gave the stock a neutral rating in a research note on monday, march 5th. Zacks investment research raised shares of bristol-myers squibb from a sell rating to a hold rating in a research note on friday, january 19th.Shares bristol-myers


vetr downgraded shares of bristol-myers squibb from a hold rating to a sell rating and set a $60.72 target price on the stock. In a research note on thursday, february 8th. Finally, BMO capital markets cut their target price on shares of bristol-myers squibb from $52.00 to $51.00 and set an underperform rating on the stock in a research note on tuesday, february 6th. Three experts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of hold and a consensus price target of $66.68.

Shares of BMY stock opened at $62.06 on wednesday. The stock has a market cap of $104,403.69, a P/E ratio of 105.19, a PEG ratio of 1.66 and a beta of 0.98.Shares bristol-myers bristol-myers squibb has a 52 week low of $51.56 and a 52 week high of $70.05. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.

Bristol-myers squibb (NYSE:BMY) last released its quarterly earnings results on monday, february 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating experts’ consensus estimates of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-myers squibb had a net margin of 4.85% and a return on equity of 35.43%. The business’s revenue was up 3.9% on a year-over-year basis.Bristol-myers squibb during the same period in the previous year, the firm earned $0.63 EPS. Sell-side experts anticipate that bristol-myers squibb will post 3.22 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on tuesday, may 1st. Shareholders of record on friday, april 6th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.58%. The ex-dividend date is thursday, april 5th. Bristol-myers squibb’s dividend payout ratio (DPR) is presently 271.19%.

Hedge funds and other institutional investors have recently bought and sold shares of the business.Shares bristol-myers cambridge investment research advisors inc. Boosted its holdings in shares of bristol-myers squibb by 11.4% in the 4th quarter. Cambridge investment research advisors inc. Now owns 209,528 shares of the biopharmaceutical company’s stock valued at $12,840,000 after buying an additional 21,391 shares in the last quarter. Ackerman capital advisors LLC acquired a new position in shares of bristol-myers squibb in the 4th quarter valued at $211,000. Fairfield bush & CO. Boosted its holdings in shares of bristol-myers squibb by 17.2% in the 4th quarter. Fairfield bush & CO. Now owns 20,855 shares of the biopharmaceutical company’s stock valued at $1,278,000 after buying an additional 3,059 shares in the last quarter.Shares bristol-myers squibb D.B. Root & company LLC acquired a new position in shares of bristol-myers squibb in the 4th quarter valued at $1,072,000. Finally, colonial trust advisors boosted its holdings in shares of bristol-myers squibb by 38.5% in the 4th quarter. Colonial trust advisors now owns 10,703 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 2,974 shares in the last quarter. Institutional investors own 71.49% of the company’s stock.

Bristol-myers squibb company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.Bristol-myers squibb quarter

banner